Synchron Stock

Founded with the mission to transform lives through advanced neurotechnology, Synchron develops cutting-edge brain-computer interface (BCI) systems. The company focuses on enabling individuals with severe paralysis to control digital devices using their thoughts, thus enhancing their independence and quality of life. Synchron's innovative technology leverages a minimally invasive endovascular procedure, similar to the placement of stents, which eliminates the need for open brain surgery. This approach not only simplifies the implantation process but also significantly reduces associated risks. Synchron's flagship product, the Stentrode™, is an implantable BCI device that records brain activity and translates it into digital commands. This allows users to perform tasks such as texting, emailing, and browsing the internet purely through thought control. The technology holds immense potential for restoring communication and interaction capabilities to individuals who have lost motor functions due to conditions like ALS, stroke, or spinal cord injury. The company is led by a team of renowned experts in neurology, bioengineering, and medical device development. Synchron's commitment to rigorous clinical research is evident through their multiple ongoing trials aimed at validating the safety and efficacy of their BCI systems. Headquartered in Brooklyn, New York, with a significant presence in Melbourne, Australia, Synchron continues to push the boundaries of what is possible in the realm of brain-computer interfaces, striving to bring new hope and independence to those affected by debilitating neurological conditions.